Two new acquisitions in Europe, in the UK and Romania
Two-year investment plan of up to 150 million euros to strengthen our global presence
Fidia Farmaceutici, following its 2024 operations, has strengthened its global presence with two new strategic operations, the first in the United Kingdom and the second in Romania. The acquisitions are part of its consolidation and growth pathway, which aims to create synergies at operational and distribution level in therapeutic areas and markets with high potential for development.
These acquisitions are part of an overall investment plan, planned for 2025–2026, amounting to about 150 million euros, aimed at consolidating Fidia’s international presence of therapeutic areas with a high strategic value.
As proof of its financial soundness, Fidia Farmaceutici used only internal resources to complete both acquisitions.
In the United Kingdom Fidia Farmaceutici acquired 100% of the capital of Altacor Ltd, which distributes ophthalmic products.
The move marks the direct entry of Fidia into the UK ophthalmology market and is an important step forward in the expansion of operational capacities and the strengthening of expertise in a key therapeutic area for the group.
In Romania Fidia has acquired Meditrina Romania S.r.l, a company incorporated under Romanian law and headquartered in Bucharest, and which operates in the distribution, promotion and marketing of medical devices, pharmaceuticals and cosmetics in the therapeutic areas of urology, gynaecology and dermatology. In addition to Romania, the company also operates in Moldova through its subsidiary, Meditrina Pharmaceutical S.r.l. – Moldova.
Already present in Romania since 2016, this move allows Fidia Farmaceutici to strengthen its distribution and management facilities, boost its own therapeutic areas and develop important synergies for the distribution of Fidia products that are already well-established on the Romanian market, thereby also reaffirming its own presence in that region.
”These two new acquisitions represent a further decisive step in our pathway to international growth and are part of the strategic operations we have accomplished in recent years”, comments Carlo Pizzocaro, President and CEO of Fidia Farmaceutici. ”We are focusing our investments in markets with high potential, with the aim of strengthening our global presence and expanding into new therapeutic areas. The expansion of our product portfolio and access to complementary channels enable us to affirm our position and offer increasingly effective solutions to meet patient needs”.
Fidia was assisted in the takeover of Altacor in the United Kingdom by McDermott Will & Emery in the legal aspects and by EY Tax&Law for tax issues.
In acquiring Meditrina Romania S.r.l, Fidia was supported by Curtis, Mallet-Prevost, Colt & Mosle LLP for legal issues, with EY Tax & Law taking care of tax issues.
